Back

Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Vericiguat, SGLT2 inhibitors and implementation Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Michael Falster

University of New South Wales Sydney, Sydney (Australia)

6 More presentations in this session

Presentation thumbnail
A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis
Doctor S. Urban (Lubin, PL)
Abstract Slides Video
Presentation thumbnail
Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction
Doctor E. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Vericiguat in a real-world heart failure population: a single-centre experience
Mr C. Palacios-Castello (Seville, ES)
Abstract Slides Video
Presentation thumbnail
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report
Doctor M. Tarnawska (Gdansk, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Vericiguat, SGLT2 inhibitors and implementation

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources